ClinicalTrials.gg
CompletedNCT06674499PeersUpdated Nov 6, 2026

Development and Evaluation of the Support Intervention for Head and Neck Cancer Patients

An interventional study of PEERS intervention and Usual care in Head and Neck Cancer, Psychotherapy and Survivor, sponsored by Xingchen Peng. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Xingchen Peng · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 6, 2026Primary outcomes revisedInterventions changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 175 studies in Head and Neck Neoplasms with a site in China — 88 open to participants now, 97 under way, 12 of them phase 3. Head and Neck Neoplasms · China.

Enrollment
52nd of 147
144 · median 84
Started
2024
with 23 others
No phase
18 of 175
8 open now
Registered
115th of 175
by date

Among the 175 studies in Head and Neck Neoplasms with a site in China, this one is the 52nd largest by enrollment of the 147 interventional ones that give a count, is one of 24 that started in 2024, is one of 18 with no phase, and was the 115th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

88 of the 175 studies in Head and Neck Neoplasms with a site in China are open now. Recruiting first, the newest first:

83 more — sign in →

All 88 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Head and Neck Neoplasms with a site in China, or all of them as a file.
02

Study summary

This randomized clinical trial evaluated the effectiveness of a structured, survivor-delivered peer-support intervention, peer-led experiential and emotional relief and support, in reducing psychological distress among patients with head and neck cancer undergoing radiotherapy.

Participants were primarily recruited from medical institutions, specifically targeting newly diagnosed patients with malignant tumors. They were randomly assigned to two different models using block randomization.

During the intervention period, trained oncology advanced practice nurses conducted questionnaire surveys for enrolled patients. During the follow-up period, these surveys were conducted every four weeks. Peripheral venous blood samples were collected at baseline and radiotherapy completion to test for biomarkers related to emotional distress.

Read the detailed description

The PEERS intervention consisted of three structured, individual, face-to-face sessions delivered by trained cancer survivor volunteers over an 8-week period. The first session, lasting 90 minutes, was conducted at radiotherapy initiation, followed by two 45-minute sessions at weeks 4 and 8. The sessions focused on preparation for radiotherapy, treatment-related emotional and practical challenges, and posttreatment adjustment. Volunteers provided emotional support and shared relevant personal experiences within predefined role boundaries.

03

Conditions studied

  • Head and Neck Cancer
  • Psychotherapy
  • Survivor
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with head and neck .
  • Experiencing psychological distress.
  • Aged between 18 and 70 years.
  • Patients scheduled to receive antitumor treatment in a day hospital or outpatient setting.
  • performance status score of 0-2.
  • Patients voluntarily participate, fully understand, and are able to independently complete the questionnaires.

Exclusion criteria

Exclusion Criteria:

  • A history of other within the past 5 years.
  • A history of any mental illness, including but not limited to: generalized anxiety disorder, depressive disorder, panic disorder, schizophrenia, or bipolar disorder.
  • Patients currently receiving other psychological treatments or taking psychiatric medications.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    PEERS intervention

    Other: PEERS intervention

  • Other
    Usual care

    Other: Usual care

Interventions

  • OtherPEERS intervention

    The intervention measures followed the principles and processes of cognitive-behavioral therapy. Three intervention sessions were conducted over a period of eight weeks. The first session lasted 90 minutes, while the subsequent sessions (in weeks 4 and 8) lasted 45 minutes each and were conducted face-to-face by the survivor volunteers.

  • OtherUsual care

    The control group, which follows the usual care, operates under the current standard of cancer treatment and follow-up. In this model, oncology healthcare professionals provide recommendations based on the specific circumstances of the patients.

06

What researchers measure

Primary outcomes

  1. Degree of improvement in emotional distress

    After the intervention period for the patients, the change in the HADS (Hospital Anxiety and Depression Scale) total score was assessed based on the scoring criteria, comparing the scores to the baseline. The HADS scoring ranges are as follows: Total Score Range: 0 to 42; Anxiety Subscale (HADS-A): 0 to 21; Depression Subscale (HADS-D): 0 to 21; Score Interpretation: 0-7: Normal range, typically indicating no significant anxiety or depression symptoms.; 8-10: Mild anxiety or depression, may warrant monitoring; 11-14: Moderate anxiety or depression, further assessment or intervention is advisable; 15 and above: Severe anxiety or depression, usually requiring professional mental health intervention; In summary, higher scores on the HADS indicate more severe symptoms of anxiety or depression.

    Time frame: From baseline to 1 month after radiotherapy completion, approximately 10.5 weeks

Secondary outcomes

  1. Levels of anxiety and depression

    Anxiety and Depression: Assessed at baseline (before intervention), every two weeks during the intervention period, and every four weeks during the follow-up period, according to the scoring criteria of the HADS. Score Range Total Score Range: 0 to 42; Anxiety Subscale (HADS-A): 0 to 21; Depression Subscale (HADS-D): 0 to 21;

    Time frame: From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks

Other outcomes

  1. Levels in quality of life

    The QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30) is a tool designed to assess the quality of life in cancer patients. It consists of 30 items covering various dimensions of quality of life, including functional status, symptoms, and overall health status. Score range: Functional status: Maximum score: 100 Minimum score: 0. Symptoms: Maximum score: 100 (note: higher scores indicate worse symptoms) Minimum score: 0. Overall health status: Maximum score: 100 Minimum score: 0.

    Time frame: From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks

  2. Levels of supportive care needs

    Supportive Care Needs Level: Evaluated at baseline (before intervention), every two weeks during the intervention period, and every four weeks during the follow-up period, using the scoring criteria of the Supportive Care Needs Survey (SCNS-SF34). Scoring method: Each item is typically rated on a 4-point Likert scale (1 = no need, 2 = low need, 3 = moderate need, 4 = high need). Total score range:Minimum score: 34 (if every item is scored as 1);Maximum score: 136 (if every item is scored as 4)。 Score significance 34-68: Low need; Indicates that the patient has minimal supportive care needs. 69-102: Moderate need; Suggests that the patient has some areas where additional support or resources may be beneficial. 103-136: High need; Reflects significant supportive care needs across multiple domains, indicating that the patient may require urgent intervention and comprehensive support.

    Time frame: From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks

  3. Levels of peripheral stress biomarkers

    Peripheral venous blood samples were collected from enrolled patients at baseline and radiotherapy completion. The stress biomarkers tested include the concentrations of cortisol and adrenocorticotropic hormone. The patient needs to lie on their back for 15 minutes before blood collection, and must avoid drinking alcohol and coffee for 12 hours before blood collection. After collection, the blood sample should be immediately sent to the laboratory for analysis.

    Time frame: From baseline to radiotherapy completion, approximately 6.5 weeks

07

Study locations

1 site
  • WestChina Hospital
    Chengdu, Sichuan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jan 2026, 13 months.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 13 months is below that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Nov 5, 2024
StartActual
Dec 1, 2024
Primary completionActual
Jan 31, 2026
CompletionActual
May 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added PEERS intervention·Usual care; removed Self-help rehabilitation model·Conventional rehabilitation model. Arms added: PEERS intervention·Usual care; arms removed: Self-help rehabilitation model·Conventional rehabilitation model
Nov 6, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameDegree of improvement in emotional distress16 weeks → From baseline to 1 month after radiotherapy completion, approximately 10.5 weeks
Nov 6, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 27, 2026
  • Time frameother outcomeLevels of Peripheral stress biomarkers16 weeks → 8 weeks
  • Descriptionother outcomeLevels of Peripheral stress biomarkers: how it is measured was reworded
What changed on Nov 6, 2026
  • RemovedLevels of improvement in quality of lifeTime frame: 16 weeks
  • RemovedLevels of Supportive care needsTime frame: 16 weeks
  • Time frameLevels of anxiety and depression16 weeks → From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks
  • DescriptionLevels of anxiety and depression: how it is measured was reworded
  • Editedother outcomeLevels of Peripheralperipheral stress biomarkersTime frame: 8 weeks → From baseline to radiotherapy completion, approximately 6.5 weeks
  • Addedother outcomeLevels in quality of lifeTime frame: From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks
  • Addedother outcomeLevels of supportive care needsTime frame: From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks
across 2 updates, Oct 27, 2026 – Nov 6, 2026
Title
Development and Evaluation of a Self-Management Model for Cancer Rehabilitation→Development and Evaluation of the Support Intervention for Head and Neck Cancer Patients
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameDegree of improvement in emotional distress16 weeks → From baseline to 1 month after radiotherapy completion, approximately 10.5 weeks
    Secondary outcomes 1 edited, 1 time frame changed, 2 added, 2 removed, 1 description edited
    What changed in the outcomes
    • RemovedLevels of improvement in quality of lifeTime frame: 16 weeks
    • RemovedLevels of Supportive care needsTime frame: 16 weeks
    • Time frameLevels of anxiety and depression16 weeks → From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks
    • DescriptionLevels of anxiety and depression: how it is measured was reworded
    • Editedother outcomeLevels of Peripheralperipheral stress biomarkersTime frame: 8 weeks → From baseline to radiotherapy completion, approximately 6.5 weeks
    • Addedother outcomeLevels in quality of lifeTime frame: From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks
    • Addedother outcomeLevels of supportive care needsTime frame: From baseline to 3 months after radiotherapy completion, approximately 18.5 weeks
    Interventions Added PEERS intervention·Usual care; removed Self-help rehabilitation model·Conventional rehabilitation model. Arms added: PEERS intervention·Usual care; arms removed: Self-help rehabilitation model·Conventional rehabilitation model
    Title Development and Evaluation of a Self-Management Model for Cancer Rehabilitation→Development and Evaluation of the Support Intervention for Head and Neck Cancer Patients
    + 3 other changes: verification date, description and conditions
  2. Oct 27, 2026
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameother outcomeLevels of Peripheral stress biomarkers16 weeks → 8 weeks
    • Descriptionother outcomeLevels of Peripheral stress biomarkers: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06674499
Lead sponsor
Xingchen Peng
Responsible party
Xingchen Peng (Professor, West China Hospital) — Sponsor-investigator
First posted
Nov 5, 2024
Start date
Dec 1, 2024
Primary completion
Jan 31, 2026
Completion
May 6, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion